Radiotherapy-induced tumors of the spine, peripheral nerve, and spinal cord: Case report and literature review

• Published in: Surgical neurology international Vol. 7; no. 5; pp. 108 - 115
• Main Authors: Falavigna, Asdrubal, da Silva, PedroGuarise, Teixeira, William
• Format: Journal Article
• Language: English
• Published: United States Scientific Scholar 2016; Medknow Publications & Media Pvt Ltd
• Subjects: Biopsy; Case reports; Chemotherapy; Fibrosarcoma; Hypertension; Literature reviews; Medical prognosis; NMR; Nuclear magnetic resonance; Pain; Patients; Radiation therapy; Spinal cord; Surgery; Surgical Neurology International: Stereotactic; Tumors; Latin America; radiotherapy; spine surgery; radiation-induced tumor; spine; Malignant peripheral nerve sheath tumor
• ISSN: 2152-7806; 2229-5097; 2152-7806
• DOI: 10.4103/2152-7806.176131

The development of a secondary malignancy in the field of radiation is a rare but well-recognized hazard of cancer treatment. The radiotherapy-induced (RT-I) tumors are even more aggressive and potentially lethal than the primary tumor. To goal of this article is to report a case of RT-I neural tumor located in the peripheral nerve and spinal cord and to perform a literature review of the subject. Thirty-year male with symptoms of hypoesthesia and dysesthesia of the L5 nerve root distribution and previous treatment of a testicular seminoma 20 years previously. The lumbar magnetic resonance imaging showed the growth of a nerve root tumor. Surgery was performed, and a fusiform tumor was resected with clear margins. The anatomopathological and immunohistochemical studies were compatible with a malignant peripheral nerve sheath tumor. A total of 30 cases were included in the review. The mean age of the patients at diagnosis of the induced tumor was 39.36 (±16.74) years. Most were male (63.3%). The main type of primary disease was neural tumors (30%). The most common type of histology was fibrosarcoma (20.0%). No difference was found in age, gender, and time of diagnosis between neural and nonneural tumors. The mean survival after the diagnosis of the secondary tumor was 10.7 months (±13.27), and neural tumors had a longer survival period (P = 0.031). The current gold standard therapy is complete resection with clear margins, since most tumors do not respond to chemotherapy and RT. The neural type of RT-I tumor presented a longer survival period.